BRIEF-Moderna Says It Presents Promising Early Data For Investigational Cancer Antigen Therapy

Reuters
Oct 13
BRIEF-<a href="https://laohu8.com/S/MRNA">Moderna</a> Says It Presents Promising Early Data For Investigational Cancer Antigen Therapy

Oct 12 (Reuters) - Moderna Inc MRNA.O:

  • MODERNA: PRESENTS PROMISING EARLY DATA FOR INVESTIGATIONAL CANCER ANTIGEN THERAPY

  • MODERNA: MRNA-4359 IN COMBINATION WITH PEMBROLIZUMAB SHOWED CONSISTENTLY MANAGEABLE SAFETY PROFILE, NO NEW IMMUNE-RELATED ADVERSE EVENTS

  • MODERNA: MRNA-4359 HAS ADVANCED INTO PHASE 2 PORTION OF ONGOING PHASE 1/2 TRIAL

Source text: [ID:]

Further company coverage: MRNA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10